After Bayer set out disappointing earnings targets for the next two years, Bayer CFO Werner Baumann told Reuters one of his strategies for fighting back--without betting the farm in the process. Like other Big Pharma firms, Bayer is eyeing emerging markets as a source of growth now that Western markets have started to stagnate. But with so many drugmakers looking to grab share of the same fast-growing markets--China, India, Brazil and the like--acquisitions have grown expensive, Baumann said. Story